Associating in vitro target binding and in vivo CNS occupancy of serotonin reuptake inhibitors in rats: The role of free drug concentrations

References

• Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. (2010). Structure and function of the blood-brain barrier. Neurobiol Dis 37:13–25.
   PubMed Web of Science ®Google Scholar
• Andersen PH, Nielsen EB, Grønvald FC, Braestrup C. (1986). Some atypical neuroleptics inhibit [3H]SCH 23390 binding in vivo. Eur J Pharmacol 120:143–144.
   PubMed Web of Science ®Google Scholar
• Becker S, Liu X. (2006). Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab Dispos 34:855–861.
   PubMed Web of Science ®Google Scholar
• Bøgesø KB, Bregnedal P, Juhl K, Wiborg O, Zong H, Topiol S. (2010). New naphthalene derivatives of citalopram discriminate between the primary and the allosteric binding sites at the human serotonin transporter. Presented at 16th World Congress on Basic and Clinical Pharmacology, Copenhagen, July 17–23.
   Google Scholar
• Bøgesø KB, Hyttel J, Christensen AV, Arnt J, Liljefors T. (1986). Chirality as determinant for neuroleptic or antidepressant action of drugs. In: Harms AF, ed. Innovative approaches in drug research. Amsterdam: Elsevier, 371–392.
   Google Scholar
• Dallas S, Miller DS, Bendayan R. (2006). Multidrug resistance-associated proteins: Expression and function in the central nervous system. Pharmacol Rev 58:140–161.
   PubMed Web of Science ®Google Scholar
• Danhof M, de Jongh J, De Lange EC, Della Pasqua O, Ploeger BA, Voskuyl RA. (2007). Mechanism-based pharmacokinetic-pharmacodynamic modeling: Biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47:357–400.
   PubMed Web of Science ®Google Scholar
• de Lange EC, Ravenstijn PG, Groenendaal D, van Steeg TJ. (2005). Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. AAPS J 7:532–543.
   PubMed Web of Science ®Google Scholar
• Di L, Umland JP, Chang G, Huang Y, Lin Z, Scott DO, Troutman MD, Liston TE. (2011). Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos 39:1270–1277.
   PubMed Web of Science ®Google Scholar
• Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U. (2011). Measurement of unbound drug exposure in brain: Modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39:353–362.
   PubMed Web of Science ®Google Scholar
• Fridén M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M. (2007). In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35:1711–1719.
   PubMed Web of Science ®Google Scholar
• Hammarlund-Udenaes M. (2010). Active-site concentrations of chemicals-are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 106:215–220.
   PubMed Web of Science ®Google Scholar
• Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A. (2008). On the rate and extent of drug delivery to the brain. Pharm Res 25:1737–1750.
   PubMed Web of Science ®Google Scholar
• Jeffrey P, Summerfield SG. (2007). Challenges for blood-brain barrier (BBB) screening. Xenobiotica 37:1135–1151.
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Maurer TS. (2002). Influence of nonspecific brain and plasma binding on CNS exposure: Implications for rational drug discovery. Biopharm Drug Dispos 23:327–338.
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM. (2007). Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: Assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther 323:346–355.
   PubMed Web of Science ®Google Scholar
• Kaufmann AM, Krise JP. (2007). Lysosomal sequestration of amine-containing drugs: Analysis and therapeutic implications. J Pharm Sci 96:729–746.
   PubMed Web of Science ®Google Scholar
• Large CH, Kalinichev M, Lucas A, Carignani C, Bradford A, Garbati N, Sartori I, Austin NE, Ruffo A, Jones DN, Alvaro G, Read KD. (2009). The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Res 85:96–106.
   PubMed Web of Science ®Google Scholar
• Larsen AK, Brennum LT, Egebjerg J, Sánchez C, Halldin C, Andersen PH. (2004). Selectivity of (3)H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects. Br J Pharmacol 141:1015–1023.
   PubMed Web of Science ®Google Scholar
• Lin JH. (2006). Tissue distribution and pharmacodynamics: A complicated relationship. Curr Drug Metab 7:39–65.
   PubMed Web of Science ®Google Scholar
• Linnet K, Ejsing TB. (2008). A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol 18:157–169.
   Google Scholar
• Liu X, Chen C, Smith BJ. (2008). Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 325:349–356.
   PubMed Web of Science ®Google Scholar
• Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M. (2009a). Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787–793.
   PubMed Web of Science ®Google Scholar
• Liu X, Vilenski O, Kwan J, Apparsundaram S, Weikert R. (2009b). Unbound brain concentration determines receptor occupancy: A correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab Dispos 37:1548–1556.
   PubMed Web of Science ®Google Scholar
• Maurer TS, Debartolo DB, Tess DA, Scott DO. (2005). Relationship between exposure and non-specific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175–181.
   PubMed Web of Science ®Google Scholar
• Milletti F, Storchi L, Sforna G, Cruciani G. (2007). New and original pKa prediction method using grid molecular interaction fields. J Chem Inf Model 47:2172–2181.
   PubMed Web of Science ®Google Scholar
• Read KD, Braggio S. (2010). Assessing brain free fraction in early drug discovery. Expert Opin Drug Metab Toxicol 6:337–344.
   PubMed Web of Science ®Google Scholar
• Sánchez C, Kreilgaard M. (2004). R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 77:391–398.
   PubMed Web of Science ®Google Scholar
• Smith DA, Di L, Kerns EH. (2010). The effect of plasma protein binding on in vivo efficacy: Misconceptions in drug discovery. Nat Rev Drug Discov 9:929–939.
   PubMed Web of Science ®Google Scholar
• Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85.
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, Stevens AJ, Metcalf AC, Osuna MC, Kilford PJ, Passchier J, Ruffo AD. (2008). Toward an improved prediction of human in vivo brain penetration. Xenobiotica 38:1518–1535.
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P. (2007). Central nervous system drug disposition: The relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205–213.
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Stevens AJ, Cutler L, del Carmen Osuna M, Hammond B, Tang SP, Hersey A, Spalding DJ, Jeffrey P. (2006). Improving the in vitro prediction of in vivo central nervous system penetration: Integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther 316:1282–1290.
   PubMed Web of Science ®Google Scholar
• Wan H, Rehngren M, Giordanetto F, Bergström F, Tunek A. (2007). High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem 50:4606–4615.
   PubMed Web of Science ®Google Scholar
• Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, Read KD. (2009). Receptor occupancy and brain free fraction. Drug Metab Dispos 37:753–760.
   PubMed Web of Science ®Google Scholar
• Westerhout J, Danhof M, De Lange EC. (2011). Preclinical prediction of human brain target site concentrations: Considerations in extrapolating to the clinical setting. J Pharm Sci 100:3577–3593.
   PubMed Web of Science ®Google Scholar